
    
      Up to 34 weeks, including a Screening Period consisting of a Screening Phase of up to 2 weeks
      and a 2-week single-blind placebo Run-in Phase, a 26-week double-blind Treatment Period, and
      a 4-week post-treatment Follow-up visit to collect safety information.
    
  